Haleon
World's largest listed pure-play consumer health firm; a Lumen Sovereign coalition member.
Last refreshed: 15 June 2026 · Appears in 1 active topic
Why is a £33bn toothpaste and painkiller giant backing Britain's sovereign AI?
Timeline for Haleon
Joined as named coalition partner for Lumen Sovereign launch
UK Startups and Innovation: Cosine builds Britain's sovereign AI model- What is Haleon and what brands does it own?
- Haleon is the world's largest listed pure-play consumer health company. Its brands include Sensodyne, Panadol, Advil, Centrum and Voltaren, and it is headquartered in Weybridge, Surrey.Source: Haleon
- When did Haleon split from GSK?
- Haleon was demerged from GSK on 18 July 2022. It had been the GSK Consumer Healthcare joint venture, in which GSK held 68% and Pfizer 32%.Source: Haleon
- Why is Haleon in Cosine's sovereign AI coalition?
- Haleon is one of thirteen regulated-industry companies named in Cosine's Lumen Sovereign Coalition on 8 June 2026, most plausibly a reference customer for regulated healthcare workflows, though no specific commitment is disclosed.Source: Lowdown
- How big is Haleon by revenue and market value?
- Haleon reported FY2025 revenue of £11,233m and carries a market capitalisation of roughly £33bn, making it a FTSE 100 constituent listed in London as HLN.Source: Haleon
Background
Haleon is the world's largest listed pure-play consumer health company, and one of the thirteen names behind Cosine's Lumen Sovereign, unveiled at London Tech Week on 8 June 2026 as what Cosine calls Britain's first sovereign frontier AI model. Among a Coalition dominated by banks and defence firms, Haleon is the consumer-health voice, most plausibly a reference customer contributing regulated healthcare workflows such as clinical-trial coordination, though no specific commitment has been disclosed.
The company was demerged from GSK on 18 July 2022, having been the GSK Consumer Healthcare joint venture in which GSK held 68% and Pfizer 32%. Its portfolio includes household brands such as Sensodyne, Panadol, Advil, Centrum and Voltaren. It is headquartered in Weybridge, Surrey.
Haleon reported FY2025 revenue of £11,233m and carries a market capitalisation of roughly £33bn. It is a FTSE 100 constituent, listed in London as HLN with a secondary New York listing, and is led by chief executive Brian McNamara. The Coalition listing places one of Britain's largest companies among the regulated-industry backers betting that sovereign on-premises AI becomes a serious enterprise market.